By Spencer Osborne : July of 2014 marked the "re-launch" of the anti-obesity drug Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) and marketing partner Eisai (OTCPK: ESALY ). Belviq had its initial launch in June of 2013 and sales
By Spencer Osborne : Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) continued to buck the seasonality factor by bringing in a 2% increase in week over week sales according to industry tracker
By EnhydrisPECorp : I think of myself as a contrarian investor with a long-term outlook. And for the most part, this approach has served me well over the years. For example, I used some of my earnings from my first job following high school graduation to buy shares of Johnson & Johnson (NYSE: JNJ
By Jason Ditz : For investors who play the small cap pharmaceutical game, Arena Pharmaceuticals (NASDAQ: ARNA ) and VIVUS Inc (NASDAQ: VVUS ) need no introduction. 2012 was the year of the weight loss drug, and consequently the year
By Spencer Osborne : The bad news for Arena Pharmaceuticals (NASDAQ: ARNA ) investors this week is that scripts were slightly down. The good news this week is that for the first time (using IMS Health
a ratio of reported adverse events to the number of scripts sold. I analyzed the data for Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) and Qsymia from Vivus (NASDAQ: VVUS ). There are a couple of items that investors should consider
Eisai's acquisition of MGI Pharma and the somewhat unconventional licensing/marketing agreement with Arena Pharmaceuticals (NASDAQ: ARNA ) for its obesity drug Belviq. Although Lexicon shareholders may regard Complete Story »
By Spencer Osborne : Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals (NASDAQ: ARNA ) continue to buck the seasonality of the weight loss sector with a 3.6% week over week gain. While 3.6% may not seem impressive
By Spencer Osborne : Vivus (NASDAQ: VVUS ) announced its quarterly earnings today and beat the street by $0.4 per share. The news sent the stock up in after hours trading, and while beating the street is always good, the company did still post a loss of $0.25 per share. Getting down to the ...
By Spencer Osborne : Orexigen (NASDAQ: OREX ) announced its Q2 financial results this morning and the loss of $0.21 cents came in line with expectations. The equity moved up early in the session because of positive outlooks for the anti-obesity drug NB32, also known as Contrave. Orexigen is ...